Picture of Hanmi Pharm logo

128940 — Hanmi Pharm News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Brief: Merck And Hanmi Pharmaceutical Enter Into Licensing Agreement To Develop Efinopegdutide

Aug 4 (Reuters) - Merck & Co Inc  MRK.N :
    * MERCK AND HANMI PHARMACEUTICAL ENTER INTO LICENSING
AGREEMENT TO
DEVELOP EFINOPEGDUTIDE, AN INVESTIGATIONAL ONCE-WEEKLY THERAPY
FOR NONALCOHOLIC STEATOHEPATITIS (NASH)
    * UNDER AGREEMENT, MERCK WILL BE GRANTED EXCLUSIVE LICENSE
TO
DEVELOP, MANUFACTURE, COMMERCIALIZE EFINOPEGDUTIDE IN US AND
GLOBALLY
    * MERCK - DATA FROM PHASE 2 STUDIES HAS PROVIDED COMPELLING
CLINICAL EVIDENCE THAT WARRANTS FURTHER EVALUATION OF
EFINOPEGDUTIDE FOR TREATMENT OF NASH
    * HANMI WILL RECEIVE UPFRONT PAYMENT OF $10 MILLION & IS
ELIGIBLE
TO RECEIVE MILESTONE PAYMENTS UP TO $860 MILLION ASSOCIATED WITH
DEVELOPMENT
    * HANMI RETAINS AN OPTION TO COMMERCIALIZE EFINOPEGDUTIDE IN
KOREA

Source text for Eikon:  ID:nBw1B8Lnla 
Further company coverage:  MRK.N 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Hanmi Pharm

See all news